Objective To investigate the clinical efficacy of edaravone combined with β-aescin sodium for treatment of elderly patients with acute cerebral hemorrhage,and the dynamic changes of tumor necrosis factor-α(TNF-α) and C-reactive protein (CRP),vascular endothelial growth factor (VEGF) levels in serum in such patients before and after treatment.Methods A total of 99 elderly patients with acute cerebral hemorrhage admitted to Henan Nanyang Second General Hospital from April 2014 to February 2016 were enrolled,and they were divided into control group (49 cases) and observation group (50 cases) according to the random digital table.Conventional treatment were given to both groups,patients in the observation group were added with edaravone 30 mg intravenous drip,2 times a day and β-aescin 20 mg intravenous drip,once daily.After treatment for consecutive 2 weeks,the clinical effect and neurological deficit score (NDS) were observed in the two groups;serum CRP levels were detected by immunonephelometry;TNF-αα and VEGF were detected by enzyme linked immunosorbent assay (ELISA).The changes of CRP,VEGF,TNF-α levels and incidence of adverse reactions before and after treatment were compared between the two groups.Results The levels of NDS,CRP,VEGF and TNF-α in both groups after treatment were significantly lower than those before treatment,and the degrees of decrease in treatment group were more significant than those in control group [NDS score:13.01 ± 1.37 vs.20.63 ± 1.68,CRP (mg/L):8.05 ± 3.97 vs.10.04 ± 4.17,VEGF (ng/L):97.25 ± 13.73 vs.116.43 ± 14.10,TNF-α (ng/L):8.15 ± 2.52 vs.11.54 ± 2.22,all P ＜ 0.05];the total effective rate in observation group was significantly higher than that in control group [92.00％ (46/50) vs.77.55％ (38/49),P ＜ 0.05].The difference of incidence of adverse reaction between observation group and control group was not statistically significant [4.00％ (2/50) vs.8.16％ (4/49),P ＞ 0.05].Conclusions Edaravone combined with β-aescin sodium for treatment of elderly patients with acute cerebral hemorrhage can effectively promote the recovery of neurological function,and its rolemight be related to the regulation of the levels of CRP,TNF-α and VEGF.%目的 探讨老年急性脑出血患者采用依达拉奉联合β-七叶皂苷钠治疗的临床疗效及患者治疗前后血清肿瘤坏死因子-α(TNF-α)、C-反应蛋白(CRP)和血管内皮生长因子(VEGF)的动态变化.方法 选取2014年4月至2016年2月河南省南阳市第二人民医院收治的99例老年急性脑出血患者,按随机数字表法分为对照组(49例)和观察组(50例).两组均给予常规治疗.观察组在常规治疗基础上加用依达拉奉静脉滴注(静滴),每次30 mg,每日2次;同时静滴β-七叶皂苷钠,每次20 mg,每日1次.连续治疗2周后,观察两组治疗后临床疗效及神经功能缺损评分(NDS);用免疫比浊法测定血清CRP水平;用酶联免疫吸附试验(ELISA)测定血清TNF-α和VEGF水平;比较两组治疗前后CRP、VEGF、TNF-α水平变化及治疗过程中不良反应发生情况.结果 两组治疗后NDS评分、CRP、VEGF、TNF-α均较治疗前明显降低,且以观察组上述指标的降低程度较对照组更显著[NDS评分(分):13.01±1.37比20.63±1.68,CRP (mg/L):8.05±3.97比10.04±4.17,VEGF (ng/L):97.25±13.73比116.43±14.10,TNF-α(ng/L):8.15±2.52比11.54±2.22,均P＜0.05];观察组治疗后总有效率显著高于对照组[92.00％ (46/50)比77.55％ (38/49),P＜0.05];观察组和对照组不良反应发生率比较差异无统计学意义[4.00％ (2/50)比8.16％(4/49),P＞0.05].结论 依达拉奉联合β-七叶皂苷钠治疗老年急性脑出血可有效促进患者神经功能恢复,其作用可能与调节CRP、TNF-α、VEGF水平有关.
展开▼
